UBS AM
PRME icon

UBS AM’s Prime Medicine PRME Stock Holding History

UBS AM’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$315K Hold
85,300
– – ﹤0.01% 2632
2026
Q1 		$297K Sell
85,300
-13,800
-14% -$52.5K ﹤0.01% 2664
2025
Q4 		$344K Buy
+99,100
New +$441K ﹤0.01% 2393

Other funds holding PRME

Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

UBS AM's PRME Position: Q2 2026 in Review

UBS AM held its Prime Medicine (PRME) position steady in Q2 2026 at 85,300 shares worth $315K. The position accounts for ﹤0.01% of the portfolio, ranked #2632.

UBS AM first reported a position in PRME in Q4 2025 and has held it in 3 quarters since. The position peaked at $344K in Q4 2025. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • UBS AM held 85,300 shares of Prime Medicine worth $315K as of Q2 2026.
  • UBS AM left its Prime Medicine share count unchanged in Q2 2026.
  • Prime Medicine made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2632 holding.
  • UBS AM first reported a position in Prime Medicine in Q4 2025 and has held it in 3 quarters since.
  • UBS AM's Prime Medicine position peaked at $344K in Q4 2025.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.